Zetia Cost in Vermont 2026: Ezetimibe Prices, Medicaid, and Savings Options

What Does Zetia Actually Cost in Vermont in 2026?

Generic ezetimibe costs roughly $15 per month at Vermont retail pharmacies when purchased cash-pay in 2026, a fraction of the brand-name Zetia list price of approximately $380 per month. The gap between those two numbers is almost entirely explained by generic competition. Merck's Zetia lost patent exclusivity, and multiple generic manufacturers now supply ezetimibe 10 mg tablets at commodity pricing.

The FDA approved ezetimibe in 2002 for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia as an adjunct to diet and, where appropriate, statin therapy [1]. The labeled dose is 10 mg orally once daily, with or without food [1].

Actual out-of-pocket costs vary by pharmacy, insurance tier, and discount card used. A 30-day supply of generic ezetimibe 10 mg at Burlington-area pharmacies, priced through GoodRx-type discount programs, ranges from about $10 to $17 depending on the specific retailer. Chains such as Walmart and Costco tend to price generic ezetimibe at the lower end of that band. Independent Vermont pharmacies may price slightly higher but often match discount-card rates when asked directly.

Patients with commercial insurance commonly land ezetimibe on Tier 2 or Tier 3 of their formulary. That translates to a copay between $30 and $60 per month depending on plan design, though high-deductible plans may require paying the full negotiated rate until the deductible is met. Negotiated rates for generic ezetimibe are typically $15 to $40 [2].

The American College of Cardiology and American Heart Association 2018 cholesterol guideline lists ezetimibe as a first-line add-on for patients who do not reach LDL-C goals on maximally tolerated statin therapy [3]. Given that recommendation, access and price matter clinically, not just financially.

The Clinical Case for Ezetimibe: What IMPROVE-IT Showed

Ezetimibe works. IMPROVE-IT (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of cardiovascular death, major coronary events, or stroke compared with simvastatin alone, with a 7-year event rate of 32.7% versus 34.7% (HR 0.936 to 95% CI 0.887-0.988, P=0.016) [4]. That absolute risk reduction of 2 percentage points translates to approximately 50 fewer events per 1,000 patients treated over 7 years [4].

LDL-C reduction with ezetimibe added to statin averages an additional 18 to 23 percentage points beyond statin monotherapy [5]. For a patient already on atorvastatin 40 mg with an LDL-C of 90 mg/dL, adding ezetimibe might push LDL-C below 70 mg/dL, which is the ACC/AHA threshold for very-high-risk patients [3].

The 2022 ACC Expert Consensus on non-statin therapy states: "Ezetimibe is the preferred second-line agent after maximally tolerated statin therapy given its cardiovascular outcome data, tolerability, and low cost" [6]. That framing matters when discussing affordability. Low cost is a guideline-level consideration, not merely a consumer preference.

Safety data from IMPROVE-IT confirmed ezetimibe's tolerability profile. Myopathy rates did not differ significantly from placebo, and hepatic enzyme elevations above three times the upper limit of normal occurred in 0.5% of the ezetimibe-simvastatin group versus 0.5% of the simvastatin-monotherapy group [4]. The FDA label notes no dose adjustment is required for mild hepatic impairment but cautions against use in moderate or severe hepatic impairment [1].

Vermont Medicaid Coverage for Ezetimibe

Vermont Medicaid (Green Mountain Care) covers ezetimibe with prior authorization. Ezetimibe does not appear on Vermont's preferred drug list as a non-restricted agent; a PA is required to confirm that the patient has an adequate indication and has tried a statin first or has a documented statin intolerance [7].

The PA process in Vermont typically requires the prescriber to submit clinical notes documenting LDL-C level, cardiovascular risk category, and prior statin trial or contraindication. Approval turnaround under Vermont Medicaid's standard review is 72 hours, though urgent requests may be processed within 24 hours [7].

Once PA is approved, Vermont Medicaid beneficiaries pay no more than a nominal copay, often $1 to $3 per fill for generic drugs. That makes ezetimibe effectively free for low-income Vermonters who clear the PA requirement [7].

Medicaid managed care organizations operating in Vermont, including Vermont Medicaid managed care plans under the Blueprint for Health, may have slightly different PA criteria. Prescribers should confirm the specific plan's preferred drug list before submitting the PA. The Green Mountain Care Board publishes updated formulary guidance that prescribers can access to check current PA criteria [7].

Patients who are dual-eligible for Medicare and Medicaid should note that Medicare Part D formularies govern ezetimibe coverage for dual-eligibles, not Vermont Medicaid directly. Most Part D plans cover generic ezetimibe on Tier 1 or Tier 2, with copays ranging from $0 to $15 [2].

Is Compounded Ezetimibe Legal in Vermont?

Compounded ezetimibe is legal in Vermont when dispensed by a licensed 503A compounding pharmacy operating under state and federal law. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare ezetimibe for a specific patient based on a valid prescription from a licensed prescriber [8]. Vermont's Board of Pharmacy licenses and inspects 503A pharmacies operating within the state, and out-of-state 503A pharmacies may ship compounded preparations to Vermont patients if they hold appropriate non-resident pharmacy licenses [9].

Compounded ezetimibe is not FDA-approved, meaning the specific compounded preparation has not undergone the same manufacturing quality review as commercially manufactured tablets [8]. Patients and prescribers should use compounded preparations only when the commercially available product does not meet a specific clinical need, such as an allergen exclusion or a dose strength not available commercially.

In practice, some Vermont patients access compounded ezetimibe at little or no additional cost through certain telehealth or membership-model pharmacy programs. The cash outlay for compounded ezetimibe through these programs may approach $0 per month for eligible patients, compared with $15 for generic tablets at retail pharmacies.

Compounded ezetimibe cannot legally be advertised or sold as equivalent to Zetia. Any claim of bioequivalence would require an FDA-reviewed abbreviated new drug application, which compounded preparations do not have [8]. Prescribers writing for compounded ezetimibe should document the clinical rationale in the chart.

Telehealth Prescribing of Ezetimibe in Vermont

Vermont law permits telehealth prescribing of ezetimibe. Vermont's telehealth statutes align with the general post-pandemic framework that allows licensed Vermont prescribers to establish a patient-provider relationship via audio-video and write prescriptions for non-controlled medications without a mandatory in-person visit [10].

Ezetimibe is not a controlled substance. A Vermont-licensed clinician can evaluate a patient's lipid panel results, cardiovascular risk, and medication history via telehealth and issue an ezetimibe prescription in a single visit. That prescription can be sent to any Vermont retail pharmacy or to a mail-order pharmacy.

National telehealth platforms that hold Vermont prescribing licenses can also provide ezetimibe prescriptions to Vermont residents. Several platforms now offer bundled lipid management services that include the prescription, follow-up LDL-C monitoring, and pharmacy coordination. Patients should confirm the platform's prescriber holds an active Vermont license before proceeding.

Follow-up lipid testing after starting ezetimibe is typically ordered at 4 to 12 weeks post-initiation to confirm LDL-C response [3]. Telehealth can handle that follow-up visit as well, though the lab draw requires an in-person phlebotomy service, which Quest and LabCorp both operate at Vermont locations.

Which Insurance Plans Cover Zetia or Ezetimibe in Vermont?

Most commercial insurance plans operating in Vermont cover generic ezetimibe, though the brand-name Zetia faces heavier restrictions. Vermont's commercial insurance market includes plans offered through the Vermont Health Connect exchange and employer-sponsored plans from carriers such as Blue Cross Blue Shield of Vermont and MVP Health Care.

Blue Cross Blue Shield of Vermont's standard individual formularies list generic ezetimibe on Tier 2 with a preferred generic copay, usually $15 to $30 per month after deductible [2]. MVP Health Care similarly covers generic ezetimibe on Tier 2 in most plan designs. Brand-name Zetia, if listed at all, typically sits on Tier 3 or Tier 4, where cost-sharing can reach $60 to $150 per month or more depending on plan design.

Employer-sponsored plans vary more widely. Some self-insured Vermont employers use pharmacy benefit managers such as CVS Caremark or OptumRx, whose formularies may place generic ezetimibe on Tier 1 at $0 to $10 copay. Employees should check the specific plan's Summary of Benefits and Coverage or call the member services number on their insurance card.

Step therapy requirements are common. Some Vermont commercial plans require documentation of a 90-day trial of a high-intensity statin before approving ezetimibe coverage. That step-therapy protocol mirrors clinical guidelines but can delay access by weeks if not anticipated [3].

Medicare Part D plans covering Vermont beneficiaries, including Humana, UnitedHealthcare, and Aetna Part D offerings, almost universally cover generic ezetimibe. The 2026 Medicare Part D redesign capped out-of-pocket costs at $2,000 annually, which reduces the catastrophic-phase burden for patients on multiple cardiovascular medications [2].

What Is the Cheapest Way to Get Ezetimibe in Vermont?

The cheapest reliable path for most Vermont patients is generic ezetimibe purchased through a GoodRx or similar discount card at a high-volume pharmacy, where prices run $10 to $17 per month. Walmart's $4/$10 generic program does not always include ezetimibe, but Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic ezetimibe at approximately $12 for a 30-day supply as of early 2026, with shipping available to Vermont [11].

For Vermont Medicaid beneficiaries, the PA approval pathway described above yields the lowest cost, often $1 to $3 per fill.

For patients with commercial insurance, using the generic instead of brand-name Zetia is the single most impactful cost reduction. Asking the prescriber to write the prescription as "ezetimibe 10 mg" or "ezetimibe 10 mg, generic substitution permitted" ensures the pharmacist dispenses the generic.

Manufacturer savings cards for brand-name Zetia are available through Merck's patient assistance program, but these cards generally cannot be used by patients with government insurance such as Medicare or Medicaid, per federal anti-kickback regulations [12]. Vermont residents with commercial insurance who insist on brand-name Zetia may reduce their copay to as low as $10 per month with an active Merck savings card, subject to eligibility terms [12].

The Merck Patient Assistance Program (PAP) provides Zetia at no cost to qualifying uninsured or underinsured Vermont patients with household incomes below 400% of the federal poverty level. Applications are available at Merck's patient assistance portal. Processing typically takes two to four weeks [12].

NeedyMeds and RxAssist maintain databases of assistance programs and Vermont-specific resources. Both sites are free to use and updated regularly [13].

Vermont Zetia Discount Programs: A Practical Comparison

Several discount mechanisms stack differently depending on insurance status. The table below describes each option by eligibility, approximate cost, and key restriction.

Generic ezetimibe via GoodRx or similar discount card: Available to any Vermont resident regardless of insurance status. Approximate monthly cost: $10 to $17. Key restriction: cannot combine with insurance copay at most pharmacies; choose whichever is cheaper.

Cost Plus Drugs (Mark Cuban): Available to any Vermont resident with shipping to a Vermont address. Approximate monthly cost: $12 plus shipping. Key restriction: no in-store pickup; delivery only.

Vermont Medicaid with PA: Available to Medicaid-enrolled Vermonters meeting clinical PA criteria. Approximate monthly cost: $1 to $3. Key restriction: prior authorization required; statin trial documentation needed.

Medicare Part D: Available to Vermont Medicare beneficiaries. Approximate monthly cost: $0 to $15 depending on plan tier. Key restriction: plan-specific formulary determines tier assignment.

Merck Savings Card (brand Zetia): Available to commercially insured Vermont residents only. Approximate monthly cost: as low as $10. Key restriction: not valid for government insurance; subject to annual cap on savings.

Merck PAP (brand Zetia): Available to uninsured or underinsured Vermont residents below income threshold. Approximate monthly cost: $0. Key restriction: income verification required; processing takes two to four weeks.

Compounded ezetimibe via 503A pharmacy: Available to Vermont patients with a valid prescription and documented clinical rationale. Approximate monthly cost: $0 to $20 depending on program. Key restriction: not FDA-approved as equivalent to Zetia; prescriber must document rationale.

Ezetimibe Dosing, Monitoring, and Drug Interactions Relevant to Vermont Prescribers

Ezetimibe 10 mg once daily is the only approved dose. No titration is needed [1]. The tablet may be taken at any time of day, with or without food, which supports adherence. Unlike statins, ezetimibe does not require evening dosing for optimal effect because its mechanism, inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, does not depend on hepatic cholesterol synthesis timing [5].

Drug interactions are limited but clinically relevant. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by approximately 55% when co-administered; ezetimibe should be taken at least 2 hours before or 4 hours after a bile acid sequestrant [1]. Cyclosporine increases ezetimibe AUC by up to 12-fold; combination requires careful monitoring in transplant patients [1]. Fibrates may increase cholesterol excretion into bile, raising gallstone risk; the FDA label recommends against combining ezetimibe with fibrates other than fenofibrate [1].

LDL-C monitoring at 4 to 12 weeks after initiation, then annually if stable, follows ACC/AHA guideline recommendations [3]. A baseline liver function panel is not required but is reasonable in patients with pre-existing hepatic risk. The National Lipid Association recommends checking a fasting lipid panel and liver function tests at the first follow-up visit after initiating any lipid-lowering drug [14].

Pregnancy and lactation: ezetimibe is FDA Pregnancy Category X for pregnant women due to animal data showing fetal harm and the absence of cholesterol-lowering benefit that would outweigh fetal risk [1]. Vermont prescribers should confirm reproductive status before prescribing in women of childbearing potential. Ezetimibe use is contraindicated during breastfeeding [1].

Renal impairment does not require dose adjustment [1]. Hepatic impairment: avoid in moderate or severe disease (Child-Pugh score 7 or above) [1].

How Ezetimibe Fits Into Vermont Cardiovascular Care in 2026

Vermont's cardiovascular disease burden reflects national trends. Ischemic heart disease remains a leading cause of death in Vermont, and LDL-C reduction is the best-validated pharmacologic strategy for reducing that risk [15]. The 2018 ACC/AHA guideline stratifies patients into risk categories and specifies LDL-C targets accordingly. Very-high-risk patients, defined as those with established ASCVD and one or more high-risk features, should achieve LDL-C below 70 mg/dL; high-risk patients should achieve below 100 mg/dL [3].

For patients on maximally tolerated statin therapy who remain above target, ezetimibe is the recommended next step before considering a PCSK9 inhibitor such as evolocumab (Repatha) or alirocumab (Praluent) [3]. The cost differential between ezetimibe at $15 per month and a PCSK9 inhibitor at $400 to $600 per month is substantial. The ACC Expert Consensus explicitly recommends a trial of ezetimibe before PCSK9 inhibitor initiation in most patients [6].

The SHARP trial (N=9,438) showed that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% in patients with chronic kidney disease (rate ratio 0.83 to 95% CI 0.74-0.94, P=0.0021) [16]. That evidence base extends ezetimibe's utility to Vermont patients with CKD, a population that carries elevated cardiovascular risk and for whom statin monotherapy may be insufficient.

Vermont prescribers working within the Blueprint for Health or with federally qualified health centers should be aware that generic ezetimibe's cost-effectiveness ratio is favorable by any standard threshold. At $15 per month, the cost per QALY gained with ezetimibe added to statin therapy falls well below the $150,000 per QALY threshold commonly cited in US health economic analyses [17].